Future Medicinal ChemistryVol. 4, No. 16 CommentaryHow the science of personalized medicines will change the clinical management of patients in the pharmacyRachel Airley & Andy EvansRachel Airley* Author for correspondenceMember of the English Pharmacy Board of the Royal Pharmaceutical Society, Division of Pharmacy & Pharmaceutical Sciences, School of Applied Sciences, University of Huddersfield, Huddersfield, West Yorkshire, UK. Search for more papers by this authorEmail the corresponding author at r.airley@hud.ac.uk & Andy EvansSchool of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, UKSearch for more papers by this authorPublished Online:16 Nov 2012https://doi.org/10.4155/fmc.12.129AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: biomarkersgenomicspersonalized medicinespharmacogenomicspharmacyproteomicsReferences1 Li J, Rix U, Fang B et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol.6(4),291–299 (2010).Crossref, Medline, CAS, Google Scholar2 Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat. Rev. Mol. Cell Biol.13(4),263–269 (2012).Crossref, Medline, CAS, Google Scholar3 Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev.22(1),50–55 (2012).Crossref, Medline, CAS, Google Scholar4 Pirmohamed M. Pharmacogenetics: past, present and future. Drug Discov. Today16(19–20),852–861 (2011).Crossref, Medline, CAS, Google Scholar5 Swen JJ, van der Straaten T, Wessels JA et al. Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19. Eur. J. Clin. Pharmacol.68(4),363–370 (2012).Crossref, Medline, CAS, Google Scholar6 Crommelin DJ, Storm G, Luijten P. ‘Personalised medicine’ through ‘personalised medicines’: time to integrate advanced, non-invasive imaging approaches and smart drug delivery systems. Int. J. Pharm.415(1–2),5–8 (2011).Crossref, Medline, CAS, Google Scholar7 Katstra WE, Palazzolo RD, Rowe CW, Giritlioglu B, Teung P, Cima MJ. Oral dosage forms fabricated by three dimensional printing. J. Control. Rel.66(1),1–9 (2000).Crossref, Medline, CAS, Google Scholar8 Florence AT, Lee VH. Personalised medicines: more tailored drugs, more tailored delivery. Int. J. Pharm.415(1–2),29–33 (2011).Crossref, Medline, CAS, Google Scholar9 Samchenko Y, Ulberg Z, Korotych O. Multipurpose smart hydrogel systems. Adv. Coll. Interface Sci.168(1–2),247–262 (2012).Crossref, Google Scholar10 Zhu Y, Li J, Li W et al. The biocompatibility of nanodiamonds and their application in drug delivery systems. Theranostics2(3),302–312 (2012).Crossref, Medline, CAS, Google Scholar11 Slastnikova TA, Rosenkranz AA, Gulak PV et al. Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery. Int. J. Nanomed.7,467–482 (2012).Medline, CAS, Google Scholar12 Wieland M, Fussenegger M. Reprogrammed cell delivery for personalized medicine. Adv. Drug Deliv. Rev. doi:10.1016/j.addr.2012.06.005 (2012) (Epub ahead of print).Medline, Google Scholar13 Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol.5(9),616–624 (2009).Crossref, Medline, CAS, Google Scholar14 Burkard ME, Jallepalli PV. Validating cancer drug targets through chemical genetics. Biochim. Biophys. Acta.1806(2),251–257 (2010).Medline, CAS, Google Scholar15 Payne K, Shabaruddin FH. Cost–effectiveness analysis in pharmacogenomics. Pharmacogenomics11(5),643–646 (2010).Crossref, Medline, Google Scholar16 McKinnon R, Anderson C. Transforming pharmaceutical education to accelerate the acceptance and implementation of personalized medicine. Am. J. Pharm. Educ.75(6),107 (2011).Crossref, Medline, Google Scholar17 Puntmann VO. How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgrad. Med. J.85(1008),538–545 (2009).Crossref, Medline, CAS, Google Scholar18 Khoury, MJ, Gwinn M, Burke W, Bowen S, Zimmern R. Will genomics widen or help heal the schism between medicine and public health? Am. J. Prev. Med.33(4),310–317 (2007).Crossref, Medline, Google Scholar19 Horvath I, Lázár Z, Gyulai N, Kollai M, Losonczy G. Exhaled biomarkers in lung cancer. Eur. Respir. J.34(1),261–275 (2009).Crossref, Medline, CAS, Google Scholar20 Hart RW, Mauk MG, Liu C et al. Point-of-care oral-based diagnostics. Oral Dis.17(8),745–752 (2011).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByModular Nanotransporters for Nuclear-Targeted Delivery of Auger Electron Emitters27 August 2018 | Frontiers in Pharmacology, Vol. 9 Vol. 4, No. 16 Follow us on social media for the latest updates Metrics Downloaded 58 times History Published online 16 November 2012 Published in print October 2012 Information© Future Science LtdKeywordsbiomarkersgenomicspersonalized medicinespharmacogenomicspharmacyproteomicsFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download